TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cellectis SA ( (CLLS) ).
On December 5, 2025, Cellectis S.A. announced a re-filing of Exhibit 4.1.3 related to its Exclusive Patent License Agreement with the University of Minnesota. This amendment allows the company to omit confidential information from material contracts without submitting a confidential treatment request. The changes include adjustments to payment structures and field of use definitions, emphasizing non-agricultural applications. These amendments are expected to streamline Cellectis’s operations by reducing administrative burdens and potentially enhancing its competitive positioning in the biotechnology sector.
The most recent analyst rating on (CLLS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is influenced primarily by its financial performance, which is challenged by ongoing losses and cash flow issues. Technical analysis shows positive momentum, providing some optimism. Valuation remains a concern due to negative earnings. The earnings call highlights strategic progress but also notes significant uncertainties.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. operates in the biotechnology industry, focusing on the development of gene-editing technologies. The company is known for its work in genome engineering, particularly in the field of agriculture and medicine, where it aims to develop innovative solutions for various applications.
Average Trading Volume: 147,880
Technical Sentiment Signal: Buy
Current Market Cap: $356.2M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.